Cambridge Trust CO Regenxbio Inc. Transaction History
Cambridge Trust CO
- $2.6 Billion
- Q1 2024
A detailed history of Cambridge Trust CO transactions in Regenxbio Inc. stock. As of the latest transaction made, Cambridge Trust CO holds 370 shares of RGNX stock, worth $2,712. This represents 0.0% of its overall portfolio holdings.
Number of Shares
370
Previous 370
-0.0%
Holding current value
$2,712
Previous $6,000
16.67%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding RGNX
# of Institutions
184Shares Held
41.5MCall Options Held
104KPut Options Held
478K-
Black Rock Inc. New York, NY8.61MShares$63.1 Million0.0% of portfolio
-
Redmile Group, LLC San Francisco, CA4.89MShares$35.9 Million3.36% of portfolio
-
Jpmorgan Chase & CO New York, NY4.14MShares$30.3 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.99MShares$21.9 Million0.0% of portfolio
-
State Street Corp Boston, MA2.78MShares$20.4 Million0.0% of portfolio
About REGENXBIO Inc.
- Ticker RGNX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,230,000
- Market Cap $317M
- Description
- REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprie...